The Lymphatic System in Disease Processes and Cancer Progression

Annual Review of Biomedical Engineering

Volumn 18, Issue , 2016, Pages 125-158

  Padera, Timothy P ^a   Meijer, Eelco F J ^a   Munn, Lance L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Lymph node metastasis; Lymph transport; Lymphangiogenesis; Lymphatic pumping; Lymphatic vessels; Lymphedema

Indexed keywords

BODY FLUIDS; DISEASE CONTROL; PHYSIOLOGY;

LYMPH NODE METASTASIS; LYMPH TRANSPORT; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; LYMPHEDEMA;

DISEASES;

CHEMOKINE;

ARTHRITIS; CANCER CELL; CANCER GROWTH; CANCER SURGERY; CELL SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; IMMUNOSURVEILLANCE; INFLAMMATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHATIC DRAINAGE; LYMPHATIC SYSTEM; LYMPHEDEMA; NEOPLASM; NONHUMAN; PATHOGENESIS; PHYSIOLOGICAL PROCESS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; LYMPHANGIOGENESIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC SYSTEM; LYMPHATIC VESSELS; LYMPHEDEMA; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84978999500     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-112315-031200     Document Type: Review

References (250)

1. ZhengW, Aspelund A, Alitalo K. 2014. Lymphangiogenic factors, mechanisms, and applications. J. Clin. Investig. 124:878-87
2. Banerji S, Ni J, Wang SX, Clasper S, Su J, et al. 1999. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144:789-801
3. Wigle JT, Oliver G. 1999. Prox1 function is required for the development of the murine lymphatic system. Cell 98:769-78
4. Martinez-Corral I, Ulvmar MH, Stanczuk L, Tatin F, Kizhatil K, et al. 2015. Nonvenous origin of dermal lymphatic vasculature. Circ. Res. 116:1649-54
5. Yang Y, Oliver G. 2014. Development of the mammalian lymphatic vasculature. J. Clin. Investig. 124:888-97
6. Zawieja DC. 2009. Contractile physiology of lymphatics. Lymphat. Res. Biol. 7:87-96
7. Dieterich LC, Seidel CD, Detmar M. 2014. Lymphatic vessels: new targets for the treatment of inflammatory diseases. Angiogenesis 17:359-71
8. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, et al. 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7:192-98
9. Mortimer PS, Rockson SG. 2014. New developments in clinical aspects of lymphatic disease. J. Clin. Investig. 124:915-21
10. HosD, Schlereth SL, Bock F,Heindl LM, Cursiefen C. 2015. Antilymphangiogenic therapy to promote transplant survival and to reduce cancer metastasis: What can we learn from the eye? Semin. Cell Dev. Biol. 38:117-30
11. Goel S, GuptaN,Walcott BP, Snuderl M, Kesler CT, et al. 2013. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J. Natl. Cancer Inst. 105:1188-201
12. Pereira ER, Jones D, Jung K, Padera TP. 2015. The lymph node microenvironment and its role in the progression of metastatic cancer. Semin. Cell Dev. Biol. 38:98-105
13. Card CM, Yu SS, Swartz MA. 2014. Emerging roles of lymphatic endothelium in regulating adaptive immunity. J. Clin. Investig. 124:943-52
14. Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, et al. 2012. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood 120:4772-82
15. Teijeira A, Russo E, Halin C. 2014. Taking the lymphatic route: dendritic cell migration to draining lymph nodes. Semin. Immunopathol. 36:261-74
16. Baluk P, Fuxe J, Hashizume H, Romano T, Lashnits E, et al. 2007. Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 204:2349-62
17. Schmid-Schönbein GW. 1990. Microlymphatics and lymph flow. Physiol. Rev. 70:987-1028
18. Witte MH, BernasMJ, Martin CP,Witte CL. 2001. Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. Microsc. Res. Tech. 55:122-45
19. Pflicke H, Sixt M. 2009. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J. Exp. Med. 206:2925-35
20. Randolph GJ, Angeli V, Swartz MA. 2005. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5:617-28
21. Schumann K, Lämmermann T, BrucknerM, Legler DF, Polleux J, et al. 2010. Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity 32:703-13
22. Miteva DO, Rutkowski JM, Dixon BJ, Kilarski W, Shields JD, Swartz MA. 2010. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ. Res. 106:920-31
23. WeberM,Hauschild R, Schwarz J,Moussion C, de Vries I, et al. 2013. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 339:328-32
24. von der Weid PY, Zawieja DC. 2004. Lymphatic smooth muscle: the motor unit of lymph drainage. Int. J. Biochem. Cell Biol. 36:1147-53
25. Davis MJ, Rahbar E, Gashev AA, Zawieja DC, Moore JE Jr. 2011. Determinants of valve gating in collecting lymphatic vessels from rat mesentery. Am. J. Physiol. Heart Circ. Physiol. 301:H48-60
26. Skalak TC, Schmid-SchönbeinGW,Zweifach BW. 1984. Newmorphological evidence for amechanism of lymph formation in skeletal muscle. Microvasc. Res. 28:95-112
27. Eisenhoffer J, Kagal A, Klein T, Johnston MG. 1995. Importance of valves and lymphangion contractions in determining pressure gradients in isolated lymphatics exposed to elevations in outflow pressure. Microvasc. Res. 49:97-110
28. Gasheva OY, ZawiejaDC, Gashev AA. 2006. Contraction-initiated NO-dependent lymphatic relaxation: a self-regulatory mechanism in rat thoracic duct. J. Physiol. 575:821-32
29. Mackay CR, Marston WL, Dudler L. 1990. Naïve and memory T cells show distinct pathways of lymphocyte recirculation. J. Exp. Med. 171:801-17
30. Pugh CW, MacPherson GG, Steer HW. 1983. Characterization of nonlymphoid cells derived from rat peripheral lymph. J. Exp. Med. 157:1758-79
31. Francisco LM, Sage PT, Sharpe AH. 2010. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236:219-42
32. Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science 348:56-61
33. Lee JW, Epardaud M, Sun J, Becker JE, Cheng AC, et al. 2007. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat. Immunol. 8:181-90
34. Nichols LA, Chen Y, Colella TA, Bennett CL, Clausen BE, Engelhard VH. 2007. Deletional selftolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J. Immunol. 179:993-1003
35. Cohen JN, Guidi CJ, Tewalt EF, Qiao H, Rouhani SJ, et al. 2010. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J. Exp. Med. 207:681-88
36. Swartz MA. 2014. Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol. Res. 2:701-7
37. Liao S, Ruddle NH. 2006. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J. Immunol. 177:3369-79
38. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. 2014. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer 14:159-72
39. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, et al. 2002. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell 3:411-23
40. AugustinHG,Koh GY, Thurston G, Alitalo K. 2009. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 10:165-77
41. Kesler CT, Pereira ER, Cui CH, Nelson GM, Masuck DJ, et al. 2015. Angiopoietin-4 increases permeability of blood vessels and promotes lymphatic dilation. FASEB J. 29:3668-77
42. Makinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, et al. 2005. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev. 19:397-410
43. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M. 2005. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 24:2885-95
44. Cao R, Björndahl MA, Religa P, Clasper S, Garvin S, et al. 2004. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6:333-45
45. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, et al. 2005. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Investig. 115:2363-72
46. Mimura T, Amano S, Usui T, Kaji Y, Oshika T, Ishii Y. 2001. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis. Exp. Eye Res. 72:71-78
47. Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, et al. 2002. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161:947-56
48. Margaris KN, Black RA. 2012. Modelling the lymphatic system: challenges and opportunities. J. R. Soc. Interface 9:601-12
49. Baxter LT, Jain RK. 1989. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res. 37:77-104
50. Roose T, SwartzMA. 2012. Multiscale modeling of lymphatic drainage from tissues using homogenization theory. J. Biomech. 45:107-15
51. Hagendoorn J, Padera TP, Kashiwagi S, Isaka N, Noda F, et al. 2004. Endothelial nitric oxide synthase regulates microlymphatic flow via collecting lymphatics. Circ. Res. 95:204-9
52. Van Helden DF, Zhao J. 2000. Lymphatic vasomotion. Clin. Exp. Pharmacol. Physiol. 27:1014-18
53. Ledvora RF, Barany M, Barany K. 1984. Myosin light chain phosphorylation and tension development in stretch-activated arterial smooth muscle. Clin. Chem. 30:2063-68
54. von der Weid PY. 2001. Review article: Lymphatic vessel pumping and inflammation\-The role of spontaneous constrictions and underlying electrical pacemaker potentials. Aliment. Pharmacol. Ther. 15:1115-29
55. TolandHM, McCloskey KD, Thornbury KD, McHale NG,Hollywood MA. 2000. Ca2+-activated Cl-current in sheep lymphatic smooth muscle. Am. J. Physiol. Cell Physiol. 279:C1327-35
56. von der Weid PY, Rahman M, Imtiaz MS, Van Helden DF. 2008. Spontaneous transient depolarizations in lymphatic vessels of the guinea pig mesentery: pharmacology and implication for spontaneous contractility. Am. J. Physiol. Heart Circ. Physiol. 295:H1989-2000
57. Van Helden DF. 1993. Pacemaker potentials in lymphatic smooth muscle of the guinea-pig mesentery. J. Physiol. 471:465-79
58. Zawieja DC, Davis KL, Schuster R, Hinds WM, Granger HJ. 1993. Distribution, propagation, and coordination of contractile activity in lymphatics. Am. J. Physiol. Heart Circ. Physiol. 264:H1283-91
59. McCloskey KD, Hollywood MA, Thornbury KD, Ward SM,McHale NG. 2002. Kit-like immunopositive cells in sheep mesenteric lymphatic vessels. Cell Tissue Res. 310:77-84
60. von der Weid PY,Crowe MJ, Van Helden DF. 1996. Endothelium-dependentmodulation of pacemaking in lymphatic vessels of the guinea-pig mesentery. J. Physiol. 493:563-75
61. Hollywood MA, McHale NG. 1994. Mediation of excitatory neurotransmission by the release of ATP and noradrenaline in sheep mesenteric lymphatic vessels. J. Physiol. 481:415-23
62. von der Weid PY, Van Helden DF. 1996. and beta-Adrenoceptor-mediated hyperpolarization in lymphatic smooth muscle of guinea pig mesentery. Am. J. Physiol. Heart Circ. Physiol. 270:H1687-95
63. DavisMJ, Lane MM, Davis AM, Durtschi D, Zawieja DC, et al. 2008. Modulation of lymphatic muscle contractility by the neuropeptide substance P. Am. J. Physiol. Heart Circ. Physiol. 295:H587-97
64. Fox JL, von der Weid PY. 2002. Effects of histamine on the contractile and electrical activity in isolated lymphatic vessels of the guinea-pig mesentery. Br. J. Pharmacol. 136:1210-18
65. Liao S, Cheng G, Conner DA, Huanga Y, Kucherlapati RS, et al. 2011. Impaired lymphatic contraction associated with immunosuppression. PNAS 108:18784-89
66. Zhao J, Van Helden DF. 2003. ET-1-associated vasomotion and vasospasm in lymphatic vessels of the guinea-pig mesentery. Br. J. Pharmacol. 140:1399-413
67. Davis MJ, Scallan JP, Wolpers JH, Muthuchamy M, Gashev AA, Zawieja DC. 2012. Intrinsic increase in lymphangion muscle contractility in response to elevated afterload. Am. J. Physiol. Heart Circ. Physiol. 303:H795-808
68. Benoit JN, Zawieja DC, Goodman AH, Granger HJ. 1989. Characterization of intact mesenteric lymphatic pump and its responsiveness to acute edemagenic stress. Am. J. Physiol. Heart Circ. Physiol. 257:H2059-69
69. McGeown JG, McHale NG, Roddie IC, Thornbury K. 1987. Peripheral lymphatic responses to outflow pressure in anaesthetized sheep. J. Physiol. 383:527-36
70. McHale N, Roddie I. 1976. The effect of transmural pressure on pumping activity in isolated bovine lymphatic vessels. J. Physiol. 261:255-69
71. Shirasawa Y, Benoit JN. 2003. Stretch-induced calcium sensitization of rat lymphatic smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 285:H2573-77
72. Johnston MG, Elias R. 1987. The regulation of lymphatic pumping. Lymphology 20:215-18
73. Davis MJ, Lane MM, Scallan JP, Gashev AA, Zawieja DC. 2007. An automated method to control preload by compensation for stress relaxation in spontaneously contracting, isometric rat mesenteric lymphatics. Microcirculation 14:603-12
74. Davis MJ, Davis AM, Lane MM, Ku CW, Gashev AA. 2009. Rate-sensitive contractile responses of lymphatic vessels to circumferential stretch. J. Physiol. 587:165-82
75. Davis MJ, Donovitz JA, Hood JD. 1992. Stretch-activated single-channel and whole cell currents in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 262:C1083-88
76. Christensen O. 1987. Mediation of cell volume regulation by Ca2+ influx through stretch-activated channels. Nature 330:66-68
77. Lee J, Ishihara A, Oxford G, Johnson B, Jacobson K. 1999. Regulation of cell movement is mediated by stretch-activated calcium channels. Nature 400:382-86
78. Gashev AA, DavisMJ, Zawieja DC. 2002. Inhibition of the active lymph pump by flow in rat mesenteric lymphatics and thoracic duct. J. Physiol. 540:1023-37
79. Kurtz KH, Moor AN, Souza-Smith FM, Breslin JW. 2014. Involvement of H1 and H2 receptors and soluble guanylate cyclase in histamine-induced relaxation of rat mesenteric collecting lymphatics. Microcirculation 21:593-605
80. Nizamutdinova IT, Maejima D, Nagai T, Bridenbaugh E, Thangaswamy S, et al. 2014. Involvement of histamine in endothelium-dependent relaxation ofmesenteric lymphatic vessels. Microcirculation 21:640-48
81. von der Weid PY, Zhao J, Van Helden DF. 2001. Nitric oxide decreases pacemaker activity in lymphatic vessels of guinea pig mesentery. Am. J. Physiol. Heart Circ. Physiol. 280:H2707-16
82. Bohlen HG, Gasheva OY, Zawieja DC. 2011. Nitric oxide formation by lymphatic bulb and valves is a major regulatory component of lymphatic pumping. Am. J. Physiol. Heart Circ. Physiol. 301:H1897-906
83. Scallan JP, Davis MJ. 2013. Genetic removal of basal nitric oxide enhances contractile activity in isolated murine collecting lymphatic vessels. J. Physiol. 591:2139-56
84. Cohen RA, Weisbrod RM, Gericke M, Yaghoubi M, Bierl C, Bolotina VM. 1999. Mechanism of nitric oxide-induced vasodilatation: refilling of intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition of store-operated Ca2+ influx. Circ. Res. 84:210-19
85. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, et al. 2002. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416:337-39
86. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. 1999. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-5
87. Mizuno R, Koller A, KaleyG. 1998. Regulation of the vasomotor activity of lymph microvessels by nitric oxide and prostaglandins. Am. J. Physiol. Regul. Integr. Comp. Physiol. 274:R790-96
88. Murphy RA,Walker JS. 1998. Inhibitory mechanisms for cross-bridge cycling: the nitric oxide-cGMP signal transduction pathway in smooth muscle relaxation. Acta Physiol. Scand. 164:373-80
89. Blatter LA, Wier WG. 1994. Nitric oxide decreases [Ca2+]i in vascular smooth muscle by inhibition of the calcium current. Cell Calcium 15:122-31
90. Shyy JYJ, Chien S. 2002. Role of integrins in endothelial mechanosensing of shear stress. Circ. Res. 91:769-75
91. Kunert C, Baish JW, Liao S, Padera TP,Munn LL. 2015. Mechanobiological oscillators control lymph flow. PNAS 112:10938-43
92. Ross TD, Coon BG, Yun S, Baeyens N, Tanaka K, et al. 2013. Integrins in mechanotransduction. Curr. Opin. Cell Biol. 25:613-18
93. Qazi H, Palomino R, Shi ZD, Munn LL, Tarbell JM. 2013. Cancer cell glycocalyx mediates mechanotransduction and flow-regulated invasion. Integr. Biol. Quant. Biosci. Nano Macro 5:1334-43
94. Tarbell JM, Simon SI, Curry FR. 2014. Mechanosensing at the vascular interface. Annu. Rev. Biomed. Eng. 16:505-32
95. Eisenhoffer J, Elias RM, JohnstonMG. 1993. Effect of outflow pressure on lymphatic pumping in vitro. Am. J. Physiol. Regul. Integr. Comp. Physiol. 265:R97-102
96. Kornuta JA, Dixon BJ. 2014. Ex vivo lymphatic perfusion system for independently controlling pressure gradient and transmural pressure in isolated vessels. Ann. Biomed. Eng. 42:1691-704
97. Cady B. 2007. Regional lymph node metastases, a singular manifestation of the process of clinical metastases in cancer: Contemporary animal research and clinical reports suggest unifying concepts. Ann. Surg. Oncol. 14:1790-800
98. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. 2002. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N. Engl. J. Med. 347:567-75
99. HalstedWS. 1907. The results of radical operations for the cure of carcinoma of the breast. Ann. Surg. 46:1-19
100. Cascinelli N, Morabito A, SantinamiM,MacKie RM, Belli F. 1998. Immediate or delayed dissection of regional nodes in patientswithmelanoma of the trunk: a randomised trial.WHOMelanoma Programme. Lancet 351:793-96
101. Starz H, Balda BR, Kramer KU, Buchels H, Wang H. 2001. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91:2110-21
102. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, et al. 2005. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087-106
103. Falkson CB. 2011. How do I deal with the axilla in patients with a positive sentinel lymph node? Curr. Treat. Options Oncol. 12:389-402
104. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, et al. 2014. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Engl. J. Med. 370:599-609
105. Hellman S. 1994. Karnofsky Memorial Lecture. Natural history of small breast cancers. J. Clin. Oncol. 12:2229-34
106. Podgrabinska S, Skobe M. 2014. Role of lymphatic vasculature in regional and distant metastases. Microvasc. Res. 95:46-52
107. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, et al. 2002. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296:1883-86
108. Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, et al. 2006. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 66:8065-75
109. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Herttuala S, et al. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61:1786-90
110. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, et al. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7:186-91
111. Padera TP, Kuo AH, Hoshida T, Liao S, Lobo J, et al. 2008. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther. 7:2272-79
112. Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA. 2009. Vascular endothelial growth factor C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 69:349-57
113. Gogineni A, Caunt M, Crow A, Lee CV, Fuh G, et al. 2013. Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis. PLOS ONE 8:e68755
114. Karnezis T, Shayan R, Caesar C, Roufail S, HarrisNC, et al. 2012. VEGF-D promotes tumormetastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 21:181-95
115. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, et al. 2006. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 66:2650-57
116. Tammela T, Saaristo A, Holopainen T, Ylä-Herttuala S, Andersson LC, et al. 2011. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci. Transl.Med. 3:69ra11
117. Escobar-Prieto A, Gonzalez G, Templeton AW, Cooper BR, Palacios E. 1971. Lymphatic channel obstruction. Patterns of altered flow dynamics. Am. J. Roentgenol. Radium Ther. Nucl. Med. 113:366-75
118. Proulx ST, Luciani P, Christiansen A, Karaman S, Blum KS, et al. 2013. Use of a PEG-conjugated bright near-infrared dye for functional imaging of rerouting of tumor lymphatic drainage after sentinel lymph node metastasis. Biomaterials 34:5128-37
119. Nathanson SD, Shah R, Chitale DA, Mahan M. 2014. Intraoperative clinical assessment and pressure measurements of sentinel lymph nodes in breast cancer. Ann. Surg. Oncol. 21:81-85
120. Kwon S, Agollah GD, Wu G, Sevick-Muraca EM. 2014. Spatio-temporal changes of lymphatic contractility and drainage patterns following lymphadenectomy in mice. PLOS ONE 9:e106034
121. Paget S. 1889. The distribution of secondary growths in cancer of the breast. Lancet 133:571-73
122. Harrell MI, Iritani BM, Ruddell A. 2007. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am. J. Pathol. 170:774-86
123. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, et al. 2006. Preparing the "soil": The primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 66:10365-76
124. Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, et al. 2015. Investigation of the lack of angiogenesis in the formation of lymph node metastases. J. Natl. Cancer Inst. 107:djv155
125. Farnsworth RH, Lackmann M, Achen MG, Stacker SA. 2014. Vascular remodeling in cancer. Oncogene 33:3496-505
126. Ogawa F, Amano H, Eshima K, Ito Y, Matsui Y, et al. 2014. Prostanoid induces premetastatic niche in regional lymph nodes. J. Clin. Investig. 124:4882-94
127. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. 2005. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLOS Med. 2:e284
128. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG,TurleyH, et al. 2005. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br. J. Cancer 93:1128-36
129. Hirakawa S, Kodama S, Kunstfeld R, KajiyaK, Brown LF,DetmarM. 2005. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201:1089-99
130. Garmy-Susini B, Avraamides CJ, Desgrosellier JS, Schmid MC, Foubert P, et al. 2013. PI3Kαactivates integrin α4β1 to establish a metastatic niche in lymph nodes. PNAS 110:9042-47
131. Lee AS, Kim DH, Lee JE, Jung YJ, Kang KP, et al. 2011. Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. Cancer Res. 71:4506-17
132. Farnsworth RH, Karnezis T, Shayan R,Matsumoto M, Nowell CJ, et al. 2011. A role for bone morphogenetic protein 4 in lymph node vascular remodeling and primary tumor growth. Cancer Res. 71:6547-57
133. Carriere V, Colisson R, Jiguet-Jiglaire C, Bellard E, Bouche G, et al. 2005. Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res. 65:11639-48
134. Deng J, Liu Y, Lee H, Herrmann A, Zhang W, et al. 2012. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 21:642-54
135. Müller A,Homey B, Soto H, Ge N, CatronD, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56
136. Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, et al. 2005. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin. Cancer Res. 11:107-12
137. Leong SP, Peng M, Zhou YM, Vaquerano JE, Chang JW. 2002. Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann. Surg. Oncol. 9:82-87
138. Barankay T, Baumgärtl H, Lübbers DW, Seidl E. 1976. Oxygen pressure in small lymphatics. Pflüg. Arch. 366:53-59
139. Hangai-Hoger N, Cabrales P, Briceno JC, Tsai AG, Intaglietta M. 2004. Microlymphatic and tissue oxygen tension in the rat mesentery. Am. J. Physiol. Heart Circ. Physiol. 286:H878-83
140. Arapandoni-Dadioti P,Giatromanolaki A, TrihiaH,Harris AL, Koukourakis MI. 1999. Angiogenesis in ductal breast carcinoma. Comparison of microvessel density between primary tumour and lymph node metastasis. Cancer Lett. 137:145-50
141. Naresh KN, Nerurkar AY, Borges AM. 2001. Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology 38:466-70
142. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. 2001. Expression of CC chemokine receptor 7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 93:1638-43
143. Ding Y, Shimada Y, MaedaM, Kawabe A, Kaganoi J, et al. 2003. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin. Cancer Res. 9:3406-12
144. Das S, Sarrou E, Podgrabinska S, Cassella M, Mungamuri SK, et al. 2013. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J. Exp. Med. 210:1509-28
145. Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. 2006. Tumour-induced immune modulation of sentinel lymph nodes. Nat. Rev. Immunol. 6:659-70
146. von Andrian UH, Mempel TR. 2003. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 3:867-78
147. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, et al. 2008. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J. Immunol. 181:3291-300
148. Deng L, Zhang H, Luan Y, Zhang J, Xing Q, et al. 2010. Accumulation of Foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin. Cancer Res. 16:4105-12
149. Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, et al. 2012. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep. 1:191-99
150. Podgrabinska S, Kamalu O, Mayer L, Shimaoka M, Snoeck H, et al. 2009. Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism. J. Immunol. 183:1767-79
151. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, et al. 2004. Effector function of human tumor-specificCD8Tcells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64:2865-73
152. Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252-64
153. Leach DR, KrummelMF, Allison JP. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-36
154. Hargadon KM, Brinkman CC, Sheasley-O'Neill SL, Nichols LA, Bullock TN, Engelhard VH. 2006. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. J. Immunol. 177:6081-90
155. Ruddell A, Harrell MI, Furuya M, Kirschbaum SB, Iritani BM. 2011. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma. Neoplasia 13:748-57
156. Li Q, Grover AC, Donald EJ, Carr A, Yu J, et al. 2005. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells. J. Immunol. 175:1424-32
157. Zirakzadeh AA, Marits P, Sherif A,Winqvist O. 2013. Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies. J. Immunol. 190:5847-55
158. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, et al. 2010. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109-13
159. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, Stewart C, Carter SL, et al. 2014. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156:1298-311
160. Naxerova K, Brachtel E, Salk JJ, Seese AM, Power K, et al. 2014. Hypermutable DNA chronicles the evolution of human colon cancer. PNAS 111:e1889-98
161. Akita H, Doki Y, Yano M, Miyata H, Miyashiro I, et al. 2009. Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. Dis. Esophagus 22:291-97
162. Medich D, McGinty J, Parda D, Karlovits S, Davis C, et al. 2001. Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis. Colon Rectum 44:1123-28
163. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, et al. 1999. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17:460-69
164. Cox C, Holloway CM, Shaheta A, Nofech-Mozes S, Wright FC. 2013. What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer? Curr. Oncol. 20:111-17
165. WuF, TamhaneM,MorrisME. 2012. Pharmacokinetics, lymph node uptake, andmechanisticPKmodel of near-infrared dye-labeled bevacizumab after IV and SC administration in mice. AAPS J. 14:252-61
166. Freeling JP, Ho RJ. 2014. Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence. PNAS 111:e2512-13
167. Thomas SN, Vokali E, Lund AW, Hubbell JA, Swartz MA. 2014. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 35:814-24
168. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, et al. 2010. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40:22-35
169. Fujita T, Teramoto K, Ozaki Y, Hanaoka J, Tezuka N, et al. 2009. Inhibition of transforming growth factor β-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res. 69:5142-50
170. Warren AG, Brorson H, Borud LJ, Slavin SA. 2007. Lymphedema: a comprehensive review. Ann. Plast. Surg. 59:464-72
171. Bellini C, Hennekam RC. 2014. Clinical disorders of primary malfunctioning of the lymphatic system. Adv. Anat. Embryol. Cell Biol. 214:187-204
172. Maclellan RA, Greene AK. 2014. Lymphedema. Semin. Pediatr. Surg. 23:191-97
173. Avraham T, Yan A, Zampell JC, Daluvoy SV, Haimovitz-Friedman A, et al. 2010. Radiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF-β1-mediated tissue fibrosis. Am. J. Physiol. Cell Physiol. 299:C589-605
174. Tiwari P, Coriddi M, Salani R, Povoski SP. 2013. Breast and gynecologic cancer-related extremity lymphedema: a review of diagnostic modalities and management options. World J. Surg. Oncol. 11:237
175. Koch S, Claesson-Welsh L. 2012. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2:a006502
176. Alders M, Al-Gazali L, Cordeiro I, Dallapiccola B, Garavelli L, et al. 2014. Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome. Hum. Genet. 133:1161-67
177. Balboa-Beltran E, Fernández-Seara MJ, Pérez-Munuzuri A, Lago R, García-Magán C, et al. 2014. A novel stop mutation in the vascular endothelial growth factor C gene (VEGFC) results in Milroy-like disease. J. Med. Genet. 51:475-78
178. García-Cruz D, Mampel A, Echeverria MI, Vargas AL, Castaneda-Cisneros G, et al. 2011. Cantu syndrome and lymphoedema. Clin. Dysmorphol. 20:32-37
179. Bennuru S, Nutman TB. 2009. Lymphangiogenesis and lymphatic remodeling induced by filarial parasites: implications for pathogenesis. PLOS Pathog. 5:e1000688
180. Nutman TB. 2013. Insights into the pathogenesis of disease in human lymphatic filariasis. Lymphat. Res. Biol. 11:144-48
181. Babu S, Nutman TB. 2012. Immunopathogenesis of lymphatic filarial disease. Semin. Immunopathol. 34:847-61
182. Chakraborty S, Gurusamy M, Zawieja DC, Muthuchamy M. 2013. Lymphatic filariasis: perspectives on lymphatic remodeling and contractile dysfunction in filarial disease pathogenesis. Microcirculation 20:349-64
183. Gebruers N, Verbelen H, De Vrieze T, Coeck D, Tjalma W. 2015. Incidence and time path of lymphedema in sentinel node negative breast cancer patients: a systematic review. Arch. Phys. Med. Rehabil. 96:1131-39
184. Swaroop MN, Ferguson CM, Horick NK, Skolny MN, Miller CL, et al. 2015. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res. Treat. 151:393-403
185. Dixon BJ, Weiler MJ. 2015. Bridging the divide between pathogenesis and detection in lymphedema. Semin. Cell Dev. Biol. 38:75-82
186. Bundred NJ, Stockton C, Keeley V, Riches K, Ashcroft L, et al. 2015. Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer. Breast Cancer Res. Treat. 151:121-29
187. Burnand KM, Glass DM, Mortimer PS, Peters AM. 2012. Lymphatic dysfunction in the apparently clinically normal contralateral limbs of patients with unilateral lower limb swelling. Clin. Nucl. Med. 37:9-13
188. Iimura T, FukushimaY,Kumita S, Ogawa R, HyakusokuH. 2015. Estimating lymphodynamic conditions and lymphovenous anastomosis efficacy using 99mTc-phytate lymphoscintigraphy with SPECT-CT in patients with lower-limb lymphedema. Plast. Reconstr. Surg. Glob. Open 3:e404
189. Blum KS, RadtkeC,Knapp WH, Pabst R, GratzKF. 2007. SPECT-CT: a valuable method to document the regeneration of lymphatics and autotransplanted lymph node fragments. Eur. J. Nucl. Med. Mol. Imaging 34:1861-67
190. Weiss M, Burgard C, Baumeister R, Strobl F, Rominger A, et al. 2014. Magnetic resonance imaging versus lymphoscintigraphy for the assessment of focal lymphatic transport disorders of the lower limb: first experiences. Nucl. Med. 53:190-96
191. Liu N, Zhang Y. 2016. Magnetic resonance lymphangiography for the study of lymphatic system in lymphedema. J. Reconstr. Microsurg. 32:66-71
192. Arrivé L, Derhy S, El Mouhadi S,Monnier-Cholley L,Menu Y, Becker C. 2016. Noncontrast magnetic resonance lymphography. J. Reconstr. Microsurg. 32:80-86
193. Sevick-Muraca EM, Kwon S, Rasmussen JC. 2014. Emerging lymphatic imaging technologies formouse and man. J. Clin. Investig. 124:905-14
194. Aldrich MB, Guilliod R, Fife CE, Maus EA, Smith L, et al. 2012. Lymphatic abnormalities in the normal contralateral arms of subjects with breast cancer-related lymphedema as assessed by near-infrared fluorescent imaging. Biomed. Opt. Express 3:1256-65
195. Mihara M, Hara H, Araki J, Kikuchi K, Narushima M, et al. 2012. Indocyanine green (ICG) lymphography is superior to lymphoscintigraphy for diagnostic imaging of early lymphedema of the upper limbs. PLOS ONE 7:e38182
196. Mehrara BJ, Greene AK. 2014. Lymphedema and obesity: Is there a link? Plast. Reconstr. Surg. 134:e154-60
197. Leung G, Baggott C, West C, Elboim C, Paul SM, et al. 2014. Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery. Lymphat. Res. Biol. 12:10-22
198. Avraham T, Zampell JC, Yan A, Elhadad S, Weitman ES, et al. 2013. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J. 27:1114-26
199. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Rüegg C, Christofori G. 2009. Myeloid cells contribute to tumor lymphangiogenesis. PLOS ONE 4:e7067
200. Lynch LL, Mendez U, Waller AB, Gillette AA, Guillory RJ 2nd, Goldman J. 2015. Fibrosis worsens chronic lymphedema in rodent tissues. Am. J. Physiol. Heart Circ. Physiol. 308:H1229-36
201. Hawinkels LJ, ten Dijke P. 2011. Exploring anti-TGF-βtherapies in cancer and fibrosis. Growth Factors 29:140-52
202. Clavin NW, Avraham T, Fernandez J, Daluvoy SV, Soares MA, et al. 2008. TGF-β1 is a negative regulator of lymphatic regeneration during wound repair. Am. J. Physiol. Heart Circ. Physiol. 295:H2113-27
203. Martin M, Lefaix J, Delanian S. 2000. TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target? Int. J. Radiat. Oncol. Biol. Phys. 47:277-90
204. Avraham T, Daluvoy S, Zampell J, Yan A,Haviv YS, et al. 2010. Blockade of transforming growth factor β1 accelerates lymphatic regeneration during wound repair. Am. J. Pathol. 177:3202-14
205. Warren LE, Miller CL, Horick N, Skolny MN, Jammallo LS, et al. 2014. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int. J. Radiat. Oncol. Biol. Phys. 88:565-71
206. Kesler CT, Kuo AH, Wong HK, Masuck DJ, Shah JL, et al. 2014. Vascular endothelial growth factor C enhances radiosensitivity of lymphatic endothelial cells. Angiogenesis 17:419-27
207. Budach W, Kammers K, Boelke E, Matuschek C. 2013. Adjuvant radiotherapy of regional lymph nodes in breast cancer-A meta-analysis of randomized trials. Radiat. Oncol. 8:267
208. Miaskowski C, Dodd M, Paul SM,WestC,HamolskyD, et al. 2013. Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. PLOS ONE 8:e60164
209. Lin S, Kim J, Lee MJ, Roche L, Yang NL, et al. 2012. Prospective transcriptomic pathway analysis of human lymphatic vascular insufficiency: identification and validation of a circulating biomarker panel. PLOS ONE 7:e52021
210. Leung N, Furniss D, Giele H. 2015. Modern surgical management of breast cancer therapy related upper limb and breast lymphoedema. Maturitas 80:384-90
211. Nguyen AT, Suami H. 2015. Laparoscopic free omental lymphatic flap for the treatment of lymphedema. Plast. Reconstr. Surg. 136:114-18
212. Lasso JM, Pinilla C, Castellano M. 2015. New refinements in greater omentum free flap transfer for severe secondary lymphedema surgical treatment. Plast. Reconstr. Surg. Glob. Open 3:e387
213. Tervala TV, Hartiala P, Tammela T, Visuri MT, Ylä-Herttuala S, et al. 2015. Growth factor therapy and lymph node graft for lymphedema. J. Surg. Res. 196:200-7
214. Headland SE, Norling LV. 2015. The resolution of inflammation: principles and challenges. Semin. Immunol. 27:149-60
215. Liao S, von der Weid PY. 2015. Lymphatic system: an active pathway for immune protection. Semin. Cell Dev. Biol. 38:83-89
216. Sakai Y, Kobayashi M. 2015. Lymphocyte 'homing' and chronic inflammation. Pathol. Int. 65:344-54
217. Ruddle NH. 2014. Lymphatic vessels and tertiary lymphoid organs. J. Clin. Investig. 124:953-59
218. Stranford S,RuddleNH.2012. Follicular dendritic cells, conduits, lymphatic vessels, and high endothelial venules in tertiary lymphoid organs: parallels with lymph node stroma. Front. Immunol. 3:350
219. Noort AR, van Zoest KP, van Baarsen LG, Maracle CX, Helder B, et al. 2015. Tertiary lymphoid structures in rheumatoid arthritis: NF-κB-inducing kinase-positive endothelial cells as central players. Am. J. Pathol. 185:1935-43
220. Aloisi F, Pujol-Borrell R. 2006. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6:205-17
221. Albuquerque RJ,Hayashi T, ChoWG, KleinmanME, Dridi S, et al. 2009. Alternatively spliced vascular endothelial growth factor receptor 2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat. Med. 15:1023-30
222. Yamagami S, Dana MR. 2001. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Investig. Ophthalmol. Vis. Sci. 42:1293-98
223. Dohlman TH, Omoto M, Hua J, StevensonW, Lee SM, et al. 2015. VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation. Transplantation 99:678-86
224. Hos D, Regenfuss B, Bock F, Onderka J, Cursiefen C. 2011. Blockade of insulin receptor substrate 1 inhibits corneal lymphangiogenesis. Investig. Ophthalmol. Vis. Sci. 52:5778-85
225. Palin NK, Savikko J, Koskinen PK. 2013. Sirolimus inhibits lymphangiogenesis in rat renal allografts, a novel mechanism to prevent chronic kidney allograft injury. Transplant Int. 26:195-205
226. Vass DG, Shrestha B, Haylor J, Hughes J, Marson L. 2012. Inflammatory lymphangiogenesis in a rat transplant model of interstitial fibrosis and tubular atrophy. Transplant Int. 25:792-800
227. Oka K,Namba Y, Ichimaru N, Moriyama T, KyoM, et al. 2009. Clinicopathological study of expression of lymphatic vessels in renal allograft biopsy after treatment for acute rejection. Transplant. Proc. 41:4154-58
228. Stuht S, Gwinner W, Franz I, Schwarz A, Jonigk D, et al. 2007. Lymphatic neoangiogenesis in human renal allografts: results from sequential protocol biopsies. Am. J. Transplant. 7:377-84
229. Dashkevich A, Heilmann C, KayserG,Germann M, Beyersdorf F, et al. 2010. Lymph angiogenesis after lung transplantation and relation to acute organ rejection in humans. Ann. Thorac. Surg. 90:406-11
230. Nykänen AI, Sandelin H, Krebs R, Keränen MA, Tuuminen R, et al. 2010. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor 3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation 121:1413-22
231. Soong TR, Pathak AP, Asano H, Fox-Talbot K, BaldwinWM 3rd. 2010. Lymphatic injury and regeneration in cardiac allografts. Transplantation 89:500-8
232. BrownK, Badar A, SunasseeK, Fernandes MA, Shariff H, et al. 2011. SPECT/CT lymphoscintigraphy of heterotopic cardiac grafts reveals novel sites of lymphatic drainage and T cell priming. Am. J. Transplant. 11:225-34
233. Kong XQ, Wang LX, Kong DG. 2007. Cardiac lymphatic interruption is a major cause for allograft failure after cardiac transplantation. Lymphat. Res. Biol. 5:45-47
234. Rockson SG. 2007. Lymphatics and the heart: the importance of visceral lymphatic function in health and disease. Lymphat. Res. Biol. 5:1-2
235. Ishii E, Shimizu A, Kuwahara N, Arai T, Kataoka M, et al. 2010. Lymphangiogenesis associated with acute cellular rejection in rat liver transplantation. Transplant. Proc. 42:4282-85
236. Kellersman R, Zhong R, Kiyochi H, Garcia B, Grant DR. 2000. Reconstruction of the intestinal lymphatic drainage after small bowel transplantation. Transplantation 69:10-16
237. Kerjaschki D. 2006. Lymphatic neoangiogenesis in renal transplants: a driving force of chronic rejection? J. Nephrol. 19:403-6
238. Seeger H, Bonani M, Segerer S. 2012. The role of lymphatics in renal inflammation. Nephrol. Dial. Transplant. 27:2634-41
239. Bouta EM, Li J, Ju Y, Brown EB, Ritchlin CT, et al. 2015. The role of the lymphatic system in inflammatory-erosive arthritis. Semin. Cell Dev. Biol. 30:90-97
240. Zhou Q, Wood R, Schwarz EM, Wang YJ, Xing L. 2010. Near-infrared lymphatic imaging demonstrates the dynamics of lymph flow and lymphangiogenesis during the acute versus chronic phases of arthritis in mice. Arthritis Rheum. 62:1881-89
241. Mandik-Nayak L, Allen PM. 2005. Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis. Immunol. Res. 32:5-13
242. Xu H, Edwards J, Banerji S, Prevo R, Jackson DG, Athanasou NA. 2003. Distribution of lymphatic vessels in normal and arthritic human synovial tissues. Ann. Rheum. Dis. 62:1227-29
243. Polzer K, Baeten D, Soleiman A, Distler J, Gerlag DM, et al. 2008. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. Ann. Rheum. Dis. 67:1610-16
244. Wauke K, Nagashima M, Ishiwata T, Asano G, Yoshino S. 2002. Expression and localization of vascular endothelial growth factor C in rheumatoid arthritis synovial tissue. J. Rheumatol. 29:34-38
245. Paavonen K, Mandelin J, Partanen T, Jussila L, Li TF, et al. 2002. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. J. Rheumatol. 29:39-45
246. Böhm M, Riemann B, Luger TA, Bonsmann G. 2000. Bilateral upper limb lymphoedema associated with psoriatic arthritis: a case report and review of the literature. Br. J. Dermatol. 143:1297-301
247. Kiely PD, Joseph AE, Mortimer PS, Bourke BE. 1994. Upper limb lymphedema associated with polyarthritis of rheumatoid type. J. Rheumatol. 21:1043-45
248. Machnik A, NeuhoferW, Jantsch J, Dahlmann A, Tammela T, et al. 2009. Macrophages regulate saltdependent volume and blood pressure by a vascular endothelial growth factor C-dependent buffering mechanism. Nat. Med. 15:545-52
249. Liu F,Mu J, Yuan Z, Lian Q, Zheng S, et al. 2011. Involvement of the lymphatic system in salt-sensitive hypertension in humans. Med. Sci. Monit. 17:542-46
250. Kwon S, Agollah GD, Chan W, Sevick-Muraca EM. 2012. Altered lymphatic function and architecture in salt-induced hypertension assessed by near-infrared fluorescence imaging. J. Biomed. Opt. 17:080504